SEC Tracker
Get the app

Biomerica BMRA

Biomerica FY 2026: revenue $4.5M, down 16%; diluted EPS −$1.30

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Biomerica reported for the year ended May 31, 2026, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$4.5M−16% from $5.3M in FY 202510-K income statement, on EDGAR
  2. Net income−$3.8MAgainst −$5.0M in FY 202510-K income statement, on EDGAR
  3. Diluted EPS−$1.30Against −$2.16 in FY 202510-K income statement, on EDGAR
  4. Cash and cash equivalents$1.3M−45% from $2.4M in FY 202510-K balance sheet, on EDGAR
  5. Cash from operations−$3.4MAgainst −$3.8M in FY 202510-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Biomerica files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Protagenic Therapeutics, Inc.\new PTIX public float $7M, Sep 30, 2025
  2. Adial Pharmaceuticals ADIL public float $6M, Jun 30, 2025
  3. AIM ImmunoTech AIM public float $6M, Jun 30, 2025
  4. Vyome Holdings HIND public float $6M, Jun 30, 2025
  5. PharmaCyte Biotech PMCB public float $6M, Oct 31, 2025